Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: Results of the FEATURE trial

Journal of Drugs in Dermatology

Volumn 15, Issue 10, 2016, Pages 1226-1234

  Gottlieb, Alice B ^a   Blauvelt, Andrew ^b   Prinz, Jörg C ^c   Papanastasiou, Philemon ^d   Pathan, Rashidkhan ^e   Nyirady, Judit ^d   Fox, Todd ^d   Papavassilis, Charis ^d  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b OREGON MEDICAL RESEARCH CENTER   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Novartis Healthcare Private Limited   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DRUG ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO; SECUKINUMAB; SECUKINUMAB ANTIBODY; TOPICAL AGENT; UNCLASSIFIED DRUG; INTERLEUKIN 17; MONOCLONAL ANTIBODY;

ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; BASAL CELL CARCINOMA; BIOLOGICAL THERAPY; CARDIOPULMONARY INSUFFICIENCY; CARDIOVASCULAR DISEASE; CELLULITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONOPHARMACOLOGY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE CLEARANCE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE REACTION; INVESTIGATOR GLOBAL ASSESSMENT; LUNG CARCINOMA; LUNG METASTASIS; LYMPHATIC SYSTEM MALIGNANCY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OROPHARYNX CANDIDIASIS; PATIENT SATISFACTION; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; PNEUMONIA; PREFILLED SYRINGE; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SELF INJECTION ASSESSMENT QUESTIONNAIRE; SELF-CONCEPT ASSESSMENT; SEPSIS; SEPTIC VASCULITIS; SKIN DISEASE ASSESSMENT; SQUAMOUS CELL CARCINOMA; SYRINGE; SYSTEMIC THERAPY; THRUSH; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VAGINA CANDIDIASIS; VASCULITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; INJECTION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PSORIASIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UTILIZATION;

ADULT; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS; INTERLEUKIN-17; MALE; MIDDLE AGED; PSORIASIS; SELF ADMINISTRATION; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; SYRINGES; TREATMENT OUTCOME;

EID: 85021308251     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371:326-338.
2. Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172:484-493.
3. Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29:1082-1090.
4. Cosentyx (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
5. Cosentyx (secukinumab) [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited. European Medicines Agency.
6. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):9-14.
7. Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222:363-374.
8. Callis Duffin K, Yeung H, Takeshita J, et al. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol. 2014;170:672-680.
9. Manary MP, Boulding W, Staelin R, et al. The patient experience and health outcomes. N Engl J Med. 2013;368:201-203.
10. Schaarschmidt ML, Umar N, Schmieder A, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol. 2013;27:187-198.
11. Scarpato S, Antivalle M, Favalli EG, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford). 2010;49:289-294.
12. Schoenknecht T, Romacker M. Prefilled syringes: why new developments are important in injectable delivery today. Prefilled Syringes: Innovations That Meet the Growing Demand. West Sussex, UK: ON drug Delivery; 2005:9-11.
13. Johanson V, Wilson B, Abrahamsson A, et al. Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional. Patient Prefer Adherence. 2012;6:703-710.
14. Farroni JS, Zwelling L, Cortes J, et al. Saving Medicare through patient-centered changes-the case of injectables. N Engl J Med. 2013;368:1572-1573.
15. Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26:23-31.
16. Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9:2.
17. Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixedinterval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73:27-36 e21.
18. Thaci D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173:777-787.